TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31486728

Group type: EXPERIMENTAL
Intervention: Patient-guided, self-management ACP approach including a Five Wishes form
Number of subjects: 800

Group type: COMPARATOR
Intervention: Structured ACP with Respecting Choices First Steps
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: After-death interviews with surrogates of patients who die during the study
Number of subjects: 800
Study: 28654558

Group type: EXPERIMENTAL
Intervention: Pecs II block under general anesthesia (group P)
Number of subjects: 64

Group type: COMPARATOR
Intervention: General anesthesia alone (group G)
Number of subjects: 64
Study: 26621498

Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SG
Number of subjects: 27
Study: 24953541

Group type: EXPERIMENTAL
Intervention: Knowledge translation intervention
Number of subjects: 40
Study: 22672578

Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser (PDL) treatment plus compression therapy (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Compression therapy (CT) alone
Number of subjects: 0
Study: 20382711

Group type: EXPERIMENTAL
Intervention: Serum VEGF-D levels > 800 pg/mL
Number of subjects: 195

Group type: COMPARATOR
Intervention: Serum VEGF-D levels < 600 pg/mL
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Serum VEGF-D levels in S-LAM
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Serum VEGF-D levels in TSC-LAM
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: VEGF-D level > 600 pg/mL
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves for VEGF-D
Number of subjects: 195
Study: 18609485

Group type: EXPERIMENTAL
Intervention: Specific lesions in patients with acute myeloid leukemia (AML)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Specific lesions in patients with acute lymphocytic leukemia (ALL)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Presence of specific lesions in AML and ALL groups
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Presence of specific orbital or ocular lesions
Number of subjects: 180
Study: 16243150

Group type: EXPERIMENTAL
Intervention: Etanercept for 24 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by etanercept for 12 weeks
Number of subjects: 100
Study: 12088968

Group type: EXPERIMENTAL
Intervention: SAB with a Sprotte needle (24-gauge)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SAB with a Quincke needle (25-gauge)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lumbar epidural block (control group)
Number of subjects: 60
Study: 9820884

Group type: EXPERIMENTAL
Intervention: Fluoride-containing formulations (disodium monofluorophosphate and sodium fluoride)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 7
Study: 9638198

Group type: EXPERIMENTAL
Intervention: Workers handling X-ray equipment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Workers handling X-ray equipment (over five years)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 2654256

Group type: EXPERIMENTAL
Intervention: Immunotherapy with cat-hair and dander extract (11 patients)
Number of subjects: 22
Study: 186090

Group type: EXPERIMENTAL
Intervention: Propranolol (0.3 mg/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Practolol (1.0 mg/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Noradrenaline (vasoconstrictor doses) with propranolol or practolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion
Number of subjects: 5
Study: 31912376

Group type: EXPERIMENTAL
Intervention: Parenting intervention (details not specified)
Number of subjects: 155
Study: 30545435

Group type: EXPERIMENTAL
Intervention: Educational outreach via a mailed letter regarding alprazolam use reduction
Number of subjects: 326

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Intervention patients who called the clinical pharmacist (CP)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Intervention patients who did not call the CP
Number of subjects: 326
Study: 28886734

Group type: EXPERIMENTAL
Intervention: Healingo Fit intervention (pedometer-based and gamified)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 144
Study: 23392651

Group type: EXPERIMENTAL
Intervention: Subliminal hint exposure (1-min movie)
Number of subjects: 509
Study: 20841418

Group type: EXPERIMENTAL
Intervention: Phenylephrine 25 μg/min
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Phenylephrine 50 μg/min
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 μg/min
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 75
Study: 18227530

Group type: EXPERIMENTAL
Intervention: Doxorubicin (part of CAF regimen)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and fluorouracil (CAF)
Number of subjects: 180
Study: 16606867

Group type: EXPERIMENTAL
Intervention: Aggressive risk factor modification strategy (targeted treatment of hypertension, dyslipidaemia, homocysteine, haemoglobin and phosphate)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Aggressive risk factor modification strategy
Number of subjects: 152
Study: 12568834

Group type: EXPERIMENTAL
Intervention: HRT (conjugated equine estrogen and micronized progesterone)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tacrine (initial dose of 40 mg/day increased up to 160 mg/day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tacrine
Number of subjects: 55
Study: 11342422

Group type: EXPERIMENTAL
Intervention: PMitCEBO (mitoxantrone, 7 mg/m2 IV on day 1)
Number of subjects: 516

Group type: COMPARATOR
Intervention: PAdriaCEBO (adriamycin, 35 mg/m2 IV on day 1)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: PMitCEBO
Number of subjects: 516

Group type: COMPARATOR
Intervention: PAdriaCEBO
Number of subjects: 516
Study: 9444547

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/d
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7840553

Group type: COMPARATOR
Intervention: Dapsone monotherapy (68 patients)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Dapsone monotherapy
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Combination of dapsone and rifampin
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Four-drug regimen (dapsone, rifampin, isoniazid, prothionamide)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 307
Study: 3281706

Group type: EXPERIMENTAL
Intervention: 1% silver sulphadiazine ophthalmic ointment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Miconazole 1%
Number of subjects: 20
Study: 1721977

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 255
Study: 412800

Group type: EXPERIMENTAL
Intervention: Floctafenine 200 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dihydrocodeine 30 mg
Number of subjects: 100
Study: 31326593

Group type: EXPERIMENTAL
Intervention: Ropivacaine (2mL of 7.5mg/mL injected into the vestibular capsule before extraction)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution injected into the vestibular capsule before extraction)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31144590

Group type: EXPERIMENTAL
Intervention: External beam radiation therapy plus brachytherapy
Number of subjects: 6643

Group type: COMPARATOR
Intervention: Radical prostatectomy plus adjuvant radiation therapy
Number of subjects: 6643
Study: 27284754

Group type: EXPERIMENTAL
Intervention: High protein intake (HPI; 0.6 g•kg‐1•bolus‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Moderate protein intake (MPI; 0.3 g•kg‐1•bolus‐1)
Number of subjects: 8
Study: 25263630

Group type: EXPERIMENTAL
Intervention: Web-based DESI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DVD-based DESI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both formats
Number of subjects: 0
Study: 22788244

Group type: EXPERIMENTAL
Intervention: CLT-driven intervention with low-level construal (LLC)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: CLT-driven intervention with high-level construal (HLC)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 411
Study: 21780185

Group type: EXPERIMENTAL
Intervention: [(11) C]NPA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Available % R(HIGH)
Number of subjects: 10
Study: 19019980

Group type: EXPERIMENTAL
Intervention: False visual feedback of hand movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual information
Number of subjects: 0
Study: 17712241

Group type: EXPERIMENTAL
Intervention: One-session HIV risk-reduction intervention during 16 weeks of outpatient cognitive behavioral SUD treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study: 15121556

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 microg vaginally 6 to 8 hours after mifepristone 200 mg
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Misoprostol 800 microg vaginally 23 to 25 hours after mifepristone 200 mg
Number of subjects: 1080
Study: 11605921

Group type: EXPERIMENTAL
Intervention: Sniffing position
Number of subjects: 456

Group type: COMPARATOR
Intervention: Simple head extension
Number of subjects: 456
Study: 9608461

Group type: EXPERIMENTAL
Intervention: Initial tension applied during ACL reconstruction (less than 80 N)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restressing of patellar tendon autografts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclic tensile loading
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unphysiologically high tension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress shielding
Number of subjects: 0
Study: 8049945

Group type: EXPERIMENTAL
Intervention: Thrombectomy with temporary arteriovenous fistula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study: 2525329

Group type: EXPERIMENTAL
Intervention: Nicorandil 5 mg twice daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg twice daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31953736

Group type: EXPERIMENTAL
Intervention: Fractional 1550-nm erbium fiber laser
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0.05% tretinoin cream
Number of subjects: 18
Study: 31053800

Group type: EXPERIMENTAL
Intervention: Intereye asymmetry of FLV%
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intereye asymmetry of GLV%
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intereye asymmetry of perfused vessel density
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intraeye asymmetry of microvascular parameters and neural structure parameters
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intereye asymmetric parameters (FLV and GLV%)
Number of subjects: 72
Study: 28662448

Group type: EXPERIMENTAL
Intervention: Exposure to particles from toasting bread
Number of subjects: 54

Group type: COMPARATOR
Intervention: Particles emitted from frying sausages and candle burning
Number of subjects: 54
Study: 25249496

Group type: EXPERIMENTAL
Intervention: 10-min teacher-implemented classroom-based activity break (AB)
Number of subjects: 118
Study: 22610748

Group type: EXPERIMENTAL
Intervention: SCH (Schisandra fruit extract and sesamin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22117666

Group type: EXPERIMENTAL
Intervention: Mid-morning snacking (10:30 am to 11:29 am)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Two or more snacks per day
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Afternoon snacking
Number of subjects: 123
Study: 19877104

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) plus methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 0
Study: 16513448

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (300 mL daily for 10 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ritonavir (400 mg daily for 10 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water (300 mL daily for 10 days)
Number of subjects: 18
Study: 12762074

Group type: EXPERIMENTAL
Intervention: Proactive role for insurance case managers and workplace ergonomic interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional case management routines (reference group)
Number of subjects: 0
Study: 10624970

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study: 8937535

Group type: EXPERIMENTAL
Intervention: Lamotrigine (75 to 400 mg daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 1569602

Group type: EXPERIMENTAL
Intervention: MTP‐PE 1 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MTP‐PE 4 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MTP‐PE
Number of subjects: 30
Study: 3901676

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31425441

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), mean daily dose 927 ± 209 mg/m²
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Algorithm based on 3 PK sampling time points (C0, C1, C2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Validation of the algorithm in a randomized group of 6 patients
Number of subjects: 23
Study: 28439633

Group type: EXPERIMENTAL
Intervention: Cystodistension
Number of subjects: 77

Group type: COMPARATOR
Intervention: Cystoscopy
Number of subjects: 77
Study: 27221208

Group type: EXPERIMENTAL
Intervention: IV brivaracetam (BRV) administered as a bolus (200 mg/day BID)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: IV brivaracetam (BRV) administered as an infusion (200 mg/day BID)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Oral brivaracetam (BRV) (200 mg/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: IV brivaracetam (BRV) (bolus or infusion)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: IV brivaracetam (BRV)
Number of subjects: 105
Study: 25543176

Group type: EXPERIMENTAL
Intervention: Floseal® group (FG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 23512758

Group type: EXPERIMENTAL
Intervention: Behaviour change counselling developed from motivational interviewing, delivered by trained clinicians using the Talking Lifestyles programme.
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Behaviour change counselling (intervention group).
Number of subjects: 1827

Group type: COMPARATOR
Intervention: Control group (no behaviour change counselling).
Number of subjects: 1827
Study: 20022460

Group type: EXPERIMENTAL
Intervention: Rotating Platform (RP) total knee arthroplasty
Number of subjects: 49

Group type: COMPARATOR
Intervention: Fixed Bearing (FB) total knee arthroplasty
Number of subjects: 49
Study: 18580887

Group type: EXPERIMENTAL
Intervention: High intake of plant protein
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: High intake of fruits and vegetables
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Increased intake of plant protein and fruits and vegetables
Number of subjects: 810
Study: 16176119

Group type: EXPERIMENTAL
Intervention: Gefitinib with rifampicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gefitinib with itraconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gefitinib with metoprolol
Number of subjects: 0
Study: 14555369

Group type: EXPERIMENTAL
Intervention: Medicine for headache
Number of subjects: 5205

Group type: EXPERIMENTAL
Intervention: Medicine for stomach ache
Number of subjects: 5205

Group type: EXPERIMENTAL
Intervention: Pain reliever use
Number of subjects: 5205

Group type: EXPERIMENTAL
Intervention: Reported medicine use trend
Number of subjects: 5205

Group type: EXPERIMENTAL
Intervention: Frequent users of medicine
Number of subjects: 5205
Study: 10506087

Group type: EXPERIMENTAL
Intervention: Standard stories that were readily comprehensible
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unusual stories with a mental framework (provided by relevant visual cues)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unusual stories without prior knowledge (no visual cues)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual cues (relevant, irrelevant, or none) provided before the story
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PET results showing brain activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medial ventral orbitofrontal cortex and left temporal pole activations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medial parietal cortex (precuneus) and left prefrontal cortex
Number of subjects: 0
Study: 8606475

Group type: EXPERIMENTAL
Intervention: Ibuprofen (three doses: 10 mg/kg intravenously followed by 5 mg/kg at 24 and 48 hours; n = 12)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ibuprofen (one dose: 10 mg/kg intravenously; n = 11)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline (n = 11)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ibuprofen (three doses)
Number of subjects: 34
Study: 2019086

Group type: EXPERIMENTAL
Intervention: 0.5% zinc citrate dentifrice
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Control dentifrice without zinc citrate
Number of subjects: 1210
Study: 6775327

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1 mg d-amphetamine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30303394

Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Health training
Number of subjects: 39
Study: 28291552

Group type: EXPERIMENTAL
Intervention: ABP 501
Number of subjects: 347

Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 347
Study: 25769303

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tenofovir
Number of subjects: 44
Study: 23296183

Group type: EXPERIMENTAL
Intervention: Zolpidem (20mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21497767

Group type: EXPERIMENTAL
Intervention: l-carnitine 50 mg/kg body weight PO
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18007268

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (5 cm H2O) applied during the first 5 hours after intubation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hi-Lo tube (HL group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SealGuard tube (SG group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: In vitro testing with positive expiratory pressure
Number of subjects: 40
Study: 16649459

Group type: EXPERIMENTAL
Intervention: 1% plain lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.25% plain bupivacaine
Number of subjects: 0
Study: 12956748

Group type: EXPERIMENTAL
Intervention: Fragranced aerosol products (two types)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clean air control
Number of subjects: 0
Study: 11192231

Group type: EXPERIMENTAL
Intervention: HFA albuterol
Number of subjects: 63

Group type: COMPARATOR
Intervention: CFC albuterol
Number of subjects: 63
Study: 1312907

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH, 2.5 g given i.v.) pretreatment prior to cisplatin infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cisplatin (CDDP, 80 mg/m2) alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP, 80 mg/m2) with GSH pretreatment
Number of subjects: 12
Study: 3899093

Group type: EXPERIMENTAL
Intervention: 2 mg purified porcine relaxin vaginally applied on the day of embryo transfer and again 3 days later
Number of subjects: 96

Group type: COMPARATOR
Intervention: Distilled water (placebo) vaginally applied on the day of embryo transfer and again 3 days later
Number of subjects: 96

Group type: COMPARATOR
Intervention: Concurrent treatment outside the trial (not specified)
Number of subjects: 96
Study: 31613356

Group type: EXPERIMENTAL
Intervention: IGMKK16E7 low-dose (0.5 g/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: IGMKK16E7 middle-dose (1 g/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: IGMKK16E7 high-dose (1.5 g/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 28586086

Group type: EXPERIMENTAL
Intervention: Transgressions against bullies
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Transgressions against friends
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Transgressions against disliked peers
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Moral transgressions across relationships
Number of subjects: 160
Study: 26214184

Group type: EXPERIMENTAL
Intervention: Lifestyle change interventions with ongoing, group-based support
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Lifestyle change interventions
Number of subjects: 84
Study: 24912062

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Competitive Employment
Number of subjects: 151
Study: 22437088

Group type: EXPERIMENTAL
Intervention: Interval training program (n=140; 8 weeks, 60-79% HR max reserve, 45-60 minutes, work/rest ratio of 1:1)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Sedentary control (n=105)
Number of subjects: 245
Study: 19731310

Group type: EXPERIMENTAL
Intervention: Urodynamics (UDS) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment based on symptoms alone
Number of subjects: 0